Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus
NCT07545408 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2026-04-22
Summary
The aim of this study is to evaluate subclinical atherosclerosis in children and adolescents with juvenile SLE by measuring carotid intima-media thickness (CIMT), and to determine its associations with traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration).
Conditions
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 0 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-01
- Primary Completion
- 2027-06-01
- Completion
- 2027-08-01
More Related Trials
-
Regulatory BCells in Systemic Lupus Erythematosus
NCT03178721 ·Status: UNKNOWN
-
Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus
NCT05146414 ·Status: COMPLETED
-
Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE
NCT02548936 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Cardiology Prevention in Systemic Lupus Erythematosus (SLE)
NCT00610805 ·Status: WITHDRAWN ·Phase: NA
-
Haematological Indices in Systemic Lupus Erythematosus
NCT04110184 ·Status: UNKNOWN
-
Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease
NCT00188188 ·Status: UNKNOWN ·Phase: PHASE4
-
The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study
NCT05588830 ·Status: UNKNOWN
-
Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals.
NCT06228222 ·Status: NOT_YET_RECRUITING
-
Assessment of Blood Indices in Systemic Lupus Erythematosus
NCT06872086 ·Status: NOT_YET_RECRUITING
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·Status: RECRUITING ·Phase: PHASE2
-
Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)
NCT00739050 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus
NCT04293510 ·Status: UNKNOWN
-
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
NCT07144514 ·Status: NOT_YET_RECRUITING
-
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
NCT07069972 ·Status: NOT_YET_RECRUITING
-
CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)
NCT01520155 ·Status: COMPLETED
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806 ·Status: RECRUITING ·Phase: PHASE1
-
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
NCT01172002 ·Status: UNKNOWN ·Phase: NA
-
Insulin Resistance and Atherosclerosis in Women With Lupus
NCT00544102 ·Status: COMPLETED
-
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NCT00000421 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
NCT06294483 ·Status: ENROLLING_BY_INVITATION
-
Anti-alpha-actinin Antibodies and Lupus Nephritis Activity
NCT07505576 ·Status: NOT_YET_RECRUITING
-
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
NCT00054938 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus
NCT05917288 ·Status: COMPLETED ·Phase: PHASE1
-
IL17 Rate and Spondyloarthritis
NCT05592574 ·Status: RECRUITING